NCT06994299 2025-11-18
PRISM
Weill Medical College of Cornell University
Phase 2 Withdrawn
Clinical Trials
8 trialsNCT06017297 2024-11-12
ESR-22-21719
Georgetown University
Phase 2 Withdrawn
NCT04625699 2023-06-06
Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
Columbia University
Phase 2 Withdrawn
NCT03982173 2023-01-26
MATILDA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT03319316 2022-01-10
SOLUTION
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT03598816 2020-08-13
PIVOT-RCC
Washington University School of Medicine
Phase 2 Withdrawn
NCT03130764 2017-12-06
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
Columbia University
Phase 2 Withdrawn
NCT03150836 2017-10-19
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
University of California, San Francisco
Phase 2 Withdrawn